Albemarle Revises FY22 Sales Guidance From $7.1B-$7.5B To $7.1B-$7.4B Vs $7.51B Est., Revises EPS Guidance From $19.25-$22.25 To $19.75-$21.75 Vs $21.28 Est.
Outlook
Full-year 2022 outlook remains strong, with net sales expected to be more than double and adjusted EBITDA expected to be nearly four times 2021 results. Ongoing strength in lithium pricing and end
